NEW YORK (GenomeWeb) -- Myriad Genetics is acquiring genetic screening firm Counsyl for $375 million in cash and common stock, the molecular diagnostics firm said last night. The move is a bid to bolster its position in the women's health space.

The acquisition will allow Myriad, a leader in the hereditary cancer genetic screening market, to expand into carrier screening with Counsyl's Foresight test, which covers more than 175 clinically actionable conditions across ethnicities, and into the rapidly growing noninvasive prenatal screening market with Counsyl's Prelude test.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

The data generated by 100,000 Genomes Project is being housed on military servers due to attacks by hackers, Naked Security reports.

A new poll finds most US adults are not familiar with personalized medicine, according to HealthDay.

Vox reports that the United Nations' Convention on Biological Diversity decided against a gene drive moratorium.

In Science this week: sequencing of neuroblastomas uncovers alterations linked to prognosis, and more.